All News

Clinical practice guideline amendments detail novel urinary biomarkers and agents that may improve Bacillus Calmette-Guerin efficacy in the management of non-muscle invasive bladder cancer.

FDA initiatives such as the Food and Drug Omnibus Reform Act will set goals and specify measures for improving representation in pediatric cancer clinical studies.

Starting April 1, 2024, Diane Simeone will be the new director of UCSD Moores Cancer Center.

Findings from the phase 3 PERSEUS trial support the supplemental New Drug Application for the daratumumab and hyaluronidase-fihj combination in transplant-eligible newly diagnosed multiple myeloma.

Patients with multiple myeloma appear to feel confident in being able to report adverse effects associated with bortezomib independently via digital tools.

Data from the phase 3 INSPIRE trial may support iruplinalkib as a new treatment option for those with advanced ALK-positive non–small cell lung cancer.

A positive CHMP opinion may lead to an approval of idecabtagene vicleucel in the European Union for patients with relapsed/refractory multiple myeloma.

Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.

Japan’s Ministry of Health, Labour, and Welfare also accepted a supplemental new drug application for lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.

Adding daratumumab to VRd induction and consolidation therapy plus lenalidomide maintenance provides a benefit with respect to MRD-negative status among patients with multiple myeloma.

At 1 and 2 years, patients with hepatocellular carcinoma and narrow surgical margins experienced encouraging recurrence-free survival rates following adjuvant radiotherapy in the phase 2 RAISE trial.

The FDA will review the supplemental biologics license application for alectinib based on data from the phase 3 ALINA study.

Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.

Results from the phase 3 MOMENTUM trial led momelotinib to being approved by the European Commission for patients with myelofibrosis plus anemia and splenomegaly.

Data from the phase 2 DESTINY-PanTumor02 trial support the supplemental biologics license application for trastuzumab deruxtecan as a treatment for those with metastatic HER2-positive solid tumors.

Results from the randomized LASRE trial support the use of laparoscopic-assisted surgery for patients with low rectal cancer.

Therapies like yoga, music therapy, acupuncture, and natural health remedies have proven to be beneficial in mitigating anxiety and depression in adults with cancer, according to Linda E. Carlson, PhD, RPsych.

uMRD-negative status linked to recurrence-free outcomes with nadofaragene firadenovec in NMIBC

Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.

Treatment with belzutifan increased the time to disease progression, according to findings from the LITESPARK-005 trial.

Findings from the phase 3 CheckMate 67T trial showed noninferiority of subcutaneous nivolumab when compared with intravenous nivolumab.

Adjuvant pembrolizumab resulted in a reduction in the risk of death in patients with ccRCC.

Treatment with nivolumab did not reach the primary endpoint of disease-free survival when compared with placebo in patients with localized renal cell carcinoma at high risk of relapse after nephrectomy in the phase 3 CheckMate 914 trial.

Lenvatinib plus pembrolizumab showed a 70% probability of greater OS benefit among patients with advanced renal cell carcinoma.

Results from the phase 2 KEYNOTE-B61 trial showed prolonged survival in patients with advanced non–clear cell renal cell carcinoma.

Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.

Results from a post hoc sensitivity analysis of the phase 3 ARASENS trial appear to affirm the primary overall survival analysis findings.

Data from the GETUG-AFU 18 trial support high-dose radiation plus long-term androgen deprivation therapy as a standard of care in high-risk prostate cancer.

Supporting data for the EMA comes from the phase 3 EV-302 trial, which assessed the efficacy of enfortumab vedotin in combination with pembrolizumab compared with chemotherapy.

Four of 5 patients with prostate cancer and ctDNA positivity had disease progression following treatment with darolutamide plus androgen deprivation therapy in a phase 2 trial.